Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Horizon Therapeutics plc
< Previous
1
2
3
4
5
6
Next >
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
January 30, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 15 (c) Announcement – Horizon Therapeutics plc
January 27, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 17 (b) Announcement – Horizon Therapeutics plc
January 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 17 (a) Announcement – Horizon Therapeutics plc
January 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations
January 18, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 2.12 Announcement – Horizon Therapeutics plc
January 12, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 06, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
January 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 03, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
December 20, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Form 8.1 Opening Position Disclosure (Horizon Therapeutics plc)
December 13, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
December 12, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 08, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
November 29, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
November 16, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
November 16, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
November 10, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
November 08, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
November 05, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations
November 02, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named to the Seramount Inclusion Index
November 01, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
October 26, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
October 22, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
October 13, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
October 12, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
October 06, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
October 06, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
October 02, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
September 29, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit